Categories
Change Password!
Reset Password!
A prospective study was performed to determine the prevalence of the PPI-partial response GERD in patients with systemic sclerosis and also identify its predictors.
Screening for
dysphagia prior to initiating gastroesophageal reflux disease (GERD) therapy is
beneficial to determine the risk of proton pump inhibitor (PPI) refractoriness
GERD in individuals with systemic sclerosis.
A prospective study
was performed to determine the prevalence of the PPI-partial response GERD in
patients with systemic sclerosis and also identify its predictors.
Systemic sclerosis patients (age 18–65 years) with GERD were treated with 20 mg omeprazole twice daily for about four weeks. At baseline and four weeks post-therapy, the following parameters were evaluated: (i) symptoms frequency by frequency scale for symptoms of GERD (FSSG), and (ii) symptom-grading severity by visual analogue scale (VAS).
A less than 50%
improvement in VAS for the severity of symptom and acid reflux score by FSSG
post-therapy was specified as PPI-partial response GERD. In total, 243
systemic sclerosis-GERD subjects were recruited; of whom 68.3% (n=166) had
diffuse cutaneous systemic sclerosis.
Half of the systemic sclerosis patients were PPI-partial response
GERD since the PPI-partial response GERD was witnessed in 131 systemic
sclerosis patients (prevalence 53.9%). According to the multivariate
assessment, the only predictor of PPI-partial response GERD (odds ratio 1.82)
in individuals with systemic sclerosis was esophageal dysphagia. Neither
systemic sclerosis subset nor the severity of skin tightness were considerably
related to the PPI-partial response GERD.
In systemic
sclerosis individuals, screening for dysphagia prior to initiating GERD therapy
is valuable to evaluate risk of PPI refractory GERD.
Scientific Reports
Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study
Chingching Foocharoen et al.
Comments (0)